HONG KONG – A Japanese technology company has reached an agreement with a UK-based orphan drug developer to co-develop and sell an orphan drug in Japan. Japan´s Teijin Pharma Ltd. entered an exclusive development and sales agreement with Sigma-Tau Pharmaceuticals Inc. that will allow Teijin to participate in the development of EZN-2279, a therapeutic agent for adenosine deaminase (ADA) deficiency, as well as to distribute the final product in Japan.